Zeplatt 3D Tablet is a combination antihypertensive medication containing Telmisartan 40mg, Cilnidipine 10mg, and Chlorthalidone 12.5mg. Telmisartan, an angiotensin II receptor blocker (ARB), lowers blood pressure by inhibiting the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance. Cilnidipine, a calcium channel blocker of the dihydropyridine class, exerts its antihypertensive action by blocking L-type and N-type calcium channels, leading to vasodilation and decreased sympathetic nerve activity. Chlorthalidone, a thiazide-like diuretic, promotes natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to blood volume reduction and sustained blood pressure control. The synergistic effect of these three agents provides effective management of hypertension, particularly in patients who require multiple mechanisms of action to achieve target blood pressure levels. Zeplatt 3D is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with elevated blood pressure. It should be used under medical supervision, with regular monitoring of blood pressure, renal function, and electrolyte levels to minimize potential adverse effects such as hypotension, electrolyte imbalance, or renal impairment.